logo

Pelvic Inflammatory Disease Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Market is Segmented by Drug Class (Tetracycline, Beta-lactam, Macrolides, Nitroimidazoles, and Other Drug Classes), Route of Administration, Distribution Channel, and Geography.

Home Industry Reports Healthcare Pelvic Inflammatory Disease Therapeutics Market - Growth, Trends, COVID-19 Impac ...

Market Snapshot

Pelvic Inflammatory Disease Therapeutics Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >5.6 %
Pelvic Inflammatory Disease Therapeutics Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pelvic inflammatory disease therapeutics (PIDT) market studied was anticipated to witness a CAGR of nearly 5.6% during the forecast period. The major factors attributing to the growth of the market are rise in urinary tract infections, sexually transmitted diseases (STDs), and severe complications associated with PID, such as increased rate of Polycystic ovary syndrome (PCOS) cases, and infertility. According to the study report published by the National Center for Biotechnology in 2018, the prevalence of lower genital tract infections, such as bacterial vaginosis, vulvovaginitis, etc., is higher in women with infertility which is projected to be continued in future which is likely to fuel the demand for efficient treatment driving the global PID market throughout the forecast period.

Scope of the Report

The pelvic inflammatory disease involves infection and inflammation of the upper genital tract (endometrium, fallopian tubes, ovaries, and pelvic peritoneum), and tissue damage caused by infection and inflammation can result in infertility, ectopic pregnancy, and chronic pelvic pain. The infection spreads from the vagina to the cervix and subsequently to the upper genital tract, with the two most commonly implicated pathogens being Chlamydia trachomatis and Neisseria gonorrhea.

Drug Class
Macrolides
Tetracycline
Beta-lactam
Nitroimidazoles
Other Drug Classes
Route of Administration
Oral
Parenteral
Other Routes of Administration
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Tetracyclines Segment is Expected to Hold the Major Market Share in the Pelvic Inflammatory Disease Therapeutics Market

Tetracycline drugs are expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment and recommendations of cephalosporin along with doxycycline, a tetracycline drug by the CDC as first-line treatment of pelvic inflammatory disease. Rapid advancements in new product development with reduced side effects, coupled with the availability of a wide range of marketed products, are expected to fuel the market. Furthermore, the disadvantages, such as increased resistance of the bacterium to other drug classes, like fluoroquinolone antibiotics, which is not recommended by the CDC for regular use in the United States, are also expected to increase the sales of the products in the segment during the forecast period.

Pelvic Inflammatory Disease Therapeutics Market Share

North America Dominates the Market and it is Expected to do the Same in the Forecast Period

North America is expected to dominate the PIDT drugs market throughout the forecast period. This dominance is mainly owing to rising incidences of menopausal disorders, polycystic ovary syndrome, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, etc., due to change in lifestyles and a rise in stress among women in the United States, which registers the highest revenue in the region. For instance, according to the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affected around 6% to 12% representing more than 5 million women of reproductive age and 1 in 8 women with a history of PID experience difficulties getting pregnant in the United States fueling the market. The availability of advanced healthcare infrastructure, increase in government expenditure for the women healthcare, rise in geriatric women population along with early product launches with enhanced quality in the region are expected to contribute its outstanding share in the growth of global market revenue over the forecast period.

Pelvic Inflammatory Disease Therapeutics Market Growth

Competitive Landscape

The PIDT market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the world. Furthermore, a steep rise in the availability of public funding for the development of these drugs is also expected to fuel the market. Some of the companies which are currently dominating the market are Bristol‑Myers Squibb Company, Pfizer Inc., Mayne Pharma, Perrigo Company PLC, and Mylan NV.

Bristol‑Myers Squibb Company, Pfizer Inc., Mayne Pharma, Perrigo Company PLC, and Mylan NV.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of STD and Infectious Diseases Across the World

      2. 4.2.2 Rise in Healthcare Awareness along with the Increasing Aging Female Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework that Delays the Approval of Products

      2. 4.3.2 Expensive Patented Products and Severe Complications Associated with the Medication

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Drug Class

      1. 5.1.1 Macrolides

      2. 5.1.2 Tetracycline

      3. 5.1.3 Beta-lactam

      4. 5.1.4 Nitroimidazoles

      5. 5.1.5 Other Drug Classes

    2. 5.2 Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Parenteral

      3. 5.2.3 Other Routes of Administration

    3. 5.3 Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc.

      2. 6.1.2 Perrigo Company PLC

      3. 6.1.3 Galderma Laboratories LP

      4. 6.1.4 Mayne Pharma

      5. 6.1.5 Bristol-Myers Squibb Company

      6. 6.1.6 Mylan NV

      7. 6.1.7 Genzyme Corporation

      8. 6.1.8 Teligent Inc.

      9. 6.1.9 F. Hoffmann-La Roche Ltd

      10. 6.1.10 Sanofi SA

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pelvic Inflammatory Disease Therapeutics Market market is studied from 2018 - 2026.

The Pelvic Inflammatory Disease Therapeutics Market is growing at a CAGR of >5.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer Inc, Perrigo Company plc, Mayne Pharma, Mylan N.V., Bristol‑Myers Squibb Company are the major companies operating in Pelvic Inflammatory Disease Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!